Electromed, Inc. Q3 2026 Earnings Recap

ELMD Q3 2026 May 13, 2026

Get alerts when ELMD reports next quarter

Electromed’s Q3 results surpassed expectations, driving a 31.2% stock rally, powered by broad-based revenue growth, significant margin expansion, and strong execution in both commercial and clinical initiatives.

Earnings Per Share Beat

$0.35 vs $0.26 est.

+34.6% surprise

Revenue Beat

18575000 vs 17600000 est.

+5.5% surprise

Market Reaction

1-Day +7.26%

See ELMD alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue grew 18.4% year-over-year to $18.6 million, supported by a 19% increase in Home Care and a 43% rebound in Hospital sales.
Operating income surged 76% to $3.8 million, reflecting meaningful margin improvement.
Diluted EPS rose 67% to $0.35, marking continued profitability gains.
The company advanced adoption with over 40% of orders through its Smart Order ePrescribe system, shortening shipment times by 5 days.
Clinical education efforts and the Triple Down on Bronchiectasis campaign are driving awareness in a large underpenetrated patient market.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ELMD on AllInvestView.

Previous Q2 2026